New Insights on Old Biomarkers Involved in Tumor Microenvironment Changes and Their Diagnostic Relevance in Non-Small Cell Lung Carcinoma.
ROC analyses
adenocarcinoma of lung
biochemical tumor markers
diagnostic biomarkers
differential diagnoses
lung cancer
malignant progression
non-small cell lung carcinoma
squamous cell carcinoma of lung
tumor microenvironment
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
13 08 2021
13 08 2021
Historique:
received:
29
06
2021
revised:
03
08
2021
accepted:
10
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Lung cancer is a multifactorial disease with a heterogeneous tumor group that hampers diagnostic and therapeutic approaches, as well as understanding of the processes that underlie its pathogenesis. Current research efforts are focused on examining alterations in the tumor microenvironment, which may affect the pathogenesis and further malignant progression in lung cancer. The aim of this study was to investigate changes in the levels of biomarkers involved in the lung tumor microenvironment and their diagnostic utility in differentiating lung cancer subtypes and stages. This study comprised 112 lung cancer patients, 50 with adenocarcinoma, 35 with squamous cell carcinoma, 13 with other non-small cell lung carcinoma subtypes, and 14 with other lung neoplasms than non-small cell lung carcinoma. Tumor markers (CEA, CYFRA 21-1, and NSE) were measured in the patients' sera and plasmas, along with IL-6, TNF-α, SAA Glucose concentrations showed statistically significant ( There is a link between biomarkers of tumor microenvironment changes and tumor markers, and combinations of these markers may be clinically useful in the differential diagnosis of adenocarcinoma and squamous cell carcinoma, as well as lung cancer stages IIB and IIA, and IIIA and IIB.
Sections du résumé
BACKGROUND
Lung cancer is a multifactorial disease with a heterogeneous tumor group that hampers diagnostic and therapeutic approaches, as well as understanding of the processes that underlie its pathogenesis. Current research efforts are focused on examining alterations in the tumor microenvironment, which may affect the pathogenesis and further malignant progression in lung cancer. The aim of this study was to investigate changes in the levels of biomarkers involved in the lung tumor microenvironment and their diagnostic utility in differentiating lung cancer subtypes and stages.
METHODS
This study comprised 112 lung cancer patients, 50 with adenocarcinoma, 35 with squamous cell carcinoma, 13 with other non-small cell lung carcinoma subtypes, and 14 with other lung neoplasms than non-small cell lung carcinoma. Tumor markers (CEA, CYFRA 21-1, and NSE) were measured in the patients' sera and plasmas, along with IL-6, TNF-α, SAA
RESULTS
Glucose concentrations showed statistically significant (
CONCLUSION
There is a link between biomarkers of tumor microenvironment changes and tumor markers, and combinations of these markers may be clinically useful in the differential diagnosis of adenocarcinoma and squamous cell carcinoma, as well as lung cancer stages IIB and IIA, and IIIA and IIB.
Identifiants
pubmed: 34439874
pii: biom11081208
doi: 10.3390/biom11081208
pmc: PMC8391392
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Aging (Albany NY). 2020 Mar 25;12(6):4757-4777
pubmed: 32209727
Pancreatology. 2012 Jul-Aug;12(4):295-304
pubmed: 22898629
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Int J Cancer. 2015 Nov 15;137(10):2332-42
pubmed: 25975224
Int J Med Sci. 2019 Jun 10;16(7):981-989
pubmed: 31341411
Metabolomics. 2018 Jun;14(6):81
pubmed: 29983671
Oncotarget. 2017 Mar 21;8(12):18901-18913
pubmed: 28121629
Transl Lung Cancer Res. 2018 Jun;7(3):220-233
pubmed: 30050761
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
Semin Cell Dev Biol. 2017 Apr;64:90-97
pubmed: 27639893
PLoS One. 2020 Aug 24;15(8):e0237947
pubmed: 32833961
Oncol Rep. 2013 Feb;29(2):469-73
pubmed: 23135313
Front Oncol. 2017 Aug 28;7:193
pubmed: 28894699
Clin Cancer Res. 2006 Sep 15;12(18):5448-53
pubmed: 17000679
J Cell Biochem. 2020 Nov;121(11):4431-4439
pubmed: 32003059
Front Oncol. 2019 Nov 15;9:1215
pubmed: 31803611
Medicine (Baltimore). 2018 Sep;97(38):e12524
pubmed: 30235773
Front Oncol. 2020 Mar 11;10:324
pubmed: 32219066
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
Genet Test Mol Biomarkers. 2009 Oct;13(5):671-8
pubmed: 19814619
Lung. 2019 Oct;197(5):601-608
pubmed: 31468132
PLoS One. 2020 May 6;15(5):e0232272
pubmed: 32374740
Int J Mol Sci. 2020 Jun 27;21(13):
pubmed: 32604993
Cancer Lett. 2020 Feb 1;470:126-133
pubmed: 31730903
Carcinogenesis. 2004 Feb;25(2):229-35
pubmed: 14604894
Cancer Biomark. 2010;9(1-6):385-96
pubmed: 22112486
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
J Clin Med. 2018 Jun 25;7(7):
pubmed: 29941786
J Cancer Res Ther. 2018 Jun;14(Supplement):S400-S404
pubmed: 29970696
Respir Investig. 2020 Jan;58(1):21-27
pubmed: 31708467
Cancer Immunol Immunother. 2021 Jul;70(7):1867-1876
pubmed: 33394095
Neoplasia. 2021 Feb;23(2):189-196
pubmed: 33373873
PeerJ. 2021 Jan 14;9:e10628
pubmed: 33520448
J Pers Med. 2020 Jul 26;10(3):
pubmed: 32722546
J Thorac Dis. 2018 Apr;10(Suppl 7):S882-S897
pubmed: 29780635
Pathobiology. 2018;85(1-2):96-107
pubmed: 29635240
Clin Cancer Res. 2005 Aug 1;11(15):5433-9
pubmed: 16061858
Cancer Med. 2018 Dec;7(12):6124-6136
pubmed: 30403008
Eur J Med Res. 2010 Nov 4;15 Suppl 2:123-7
pubmed: 21147639
J Thorac Dis. 2018 Jul;10(7):4032-4041
pubmed: 30174846
Autoimmunity. 2018 Jun;51(4):191-198
pubmed: 29869537
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236
Am J Respir Crit Care Med. 2016 Dec 1;194(11):1403-1412
pubmed: 27299180
Tumour Biol. 2014 May;35(5):4581-7
pubmed: 24408019
Adv Med Sci. 2013;58(1):73-82
pubmed: 23640949
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Biomed Res Int. 2017;2017:9352015
pubmed: 28770228